Alnylam Pharmace. buy Piper Sandler
Summary
This prediction is currently active. With a performance of 47.76% the BUY prediction by Piper_Sandler is a big success. This prediction currently runs until 14.12.24. The prediction end date can be changed by Piper_Sandler at any time. Piper_Sandler has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Alnylam Pharmace. | -0.674% | -0.674% |
iShares Core DAX® | 1.937% | 1.473% |
iShares Nasdaq 100 | -1.186% | -0.040% |
iShares Nikkei 225® | 1.938% | 4.205% |
iShares S&P 500 | -0.023% | 0.109% |
Comments by Piper_Sandler for this prediction
In the thread Alnylam Pharmace. diskutieren